{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:01Z","timestamp":1793048461550,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant from the Korean government","award":["2019R1F1A1053841"],"award-info":[{"award-number":["2019R1F1A1053841"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glutamate is implicated in migraine pathogenesis including central sensitization and pain transmission. Altered plasma glutamate levels has been noted in migraine. Chronic migraine (CM) presented a higher degree of central sensitization and pain transmission than episodic migraine (EM). However, no study has evaluated plasma glutamate levels separately in EM and CM. This study aimed to assess plasma glutamate levels in EM and CM compared to controls. An enzyme-linked immunosorbent assay was used to assess plasma glutamate levels in females with EM (n\u2009=\u200998) and CM (n\u2009=\u200992) as well as controls (n\u2009=\u200950). Plasma glutamate levels in participants with EM (median and interquartile range, 49.73 [40.82\u201366.12] \u03bcmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and CM (58.70 [44.64\u201372.46] \u03bcmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were significantly higher than those in controls (38.79 [29.50\u201353.60] \u03bcmol\/L). Glutamate levels were not significantly different between participants with EM and CM (<jats:italic>p<\/jats:italic>\u2009=\u20090.075). There was no significant association of plasma glutamate levels with headache frequency (exponential and 95% confidence interval, 1.285 [0.941\u20131.755]) and intensity (mild, 59.95 [59.95\u201359.95] \u03bcmol\/L vs. moderate, 52.76 [40.83\u2013106.89] \u03bcmol\/L vs. severe, 55.16 [42.34\u201368.03] \u03bcmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.472). The plasma glutamate level is a potential indicator for EM and CM.<\/jats:p>","DOI":"10.1038\/s41598-022-10883-9","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:03:47Z","timestamp":1651136627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Interictal plasma glutamate levels are elevated in individuals with episodic and chronic migraine"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-1308","authenticated-orcid":false,"given":"Chae Gyu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-1346","authenticated-orcid":false,"given":"Min Kyung","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"10883_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/187152707781387279","volume":"6","author":"M Vikelis","year":"2007","unstructured":"Vikelis, M. & Mitsikostas, D. D. The role of glutamate and its receptors in migraine. CNS Neurol. Disord. Drug Targets 6, 251\u2013257 (2007).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10883_CR2","doi-asserted-by":"publisher","first-page":"1007s","DOI":"10.1093\/jn\/130.4.1007S","volume":"130","author":"BS Meldrum","year":"2000","unstructured":"Meldrum, B. S. Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J. Nutr. 130, 1007s\u20131015s (2000).","journal-title":"J. Nutr."},{"key":"10883_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"SD Silberstein","year":"2004","unstructured":"Silberstein, S. D., Neto, W., Schmitt, J. & Jacobs, D. Topiramate in migraine prevention: Results of a large controlled trial. Arch. Neurol. 61, 490\u2013495 (2004).","journal-title":"Arch. Neurol."},{"key":"10883_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e318170577f","volume":"32","author":"PE Bermejo","year":"2009","unstructured":"Bermejo, P. E. & Dorado, R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin. Neuropharmacol. 32, 103\u2013106 (2009).","journal-title":"Clin. Neuropharmacol."},{"key":"10883_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0022-510X(98)00023-9","volume":"156","author":"Z Alam","year":"1998","unstructured":"Alam, Z., Coombes, N., Waring, R. H., Williams, A. C. & Steventon, G. B. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J. Neurol. Sci. 156, 102\u2013106 (1998).","journal-title":"J. Neurol. Sci."},{"key":"10883_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/j.1468-1331.2012.03693.x","volume":"19","author":"C Ragginer","year":"2012","unstructured":"Ragginer, C. et al. Reduced urinary glutamate levels are associated with the frequency of migraine attacks in females. Eur. J. Neurol. 19, 1146\u20131150 (2012).","journal-title":"Eur. J. Neurol."},{"key":"10883_CR7","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1177\/0333102413487444","volume":"33","author":"F Campos","year":"2013","unstructured":"Campos, F. et al. Glutamate oxaloacetate transaminase: A new key in the dysregulation of glutamate in migraine patients. Cephalalgia 33, 1148\u20131154 (2013).","journal-title":"Cephalalgia"},{"key":"10883_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1468-2982.1995.015002132.x","volume":"15","author":"AR Cananzi","year":"1995","unstructured":"Cananzi, A. R., D\u2019Andrea, G., Perini, F., Zamberlan, F. & Welch, K. M. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 15, 132\u2013135 (1995).","journal-title":"Cephalalgia"},{"key":"10883_CR9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/WNL.40.10.1582","volume":"40","author":"MD Ferrari","year":"1990","unstructured":"Ferrari, M. D., Odink, J., Bos, K. D., Malessy, M. J. & Bruyn, G. W. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40, 1582\u20131586 (1990).","journal-title":"Neurology"},{"key":"10883_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1468-2982.2003.00552.x","volume":"23","author":"V Gallai","year":"2003","unstructured":"Gallai, V. et al. Glutamate and nitric oxide pathway in chronic daily headache: Evidence from cerebrospinal fluid. Cephalalgia 23, 166\u2013174 (2003).","journal-title":"Cephalalgia"},{"key":"10883_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1177\/0333102417742366","volume":"38","author":"JH Nam","year":"2018","unstructured":"Nam, J. H., Lee, H. S., Kim, J., Kim, J. & Chu, M. K. Salivary glutamate is elevated in individuals with chronic migraine. Cephalalgia 38, 1485\u20131492 (2018).","journal-title":"Cephalalgia"},{"key":"10883_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1468-2982.2004.00750.x","volume":"24","author":"MF Peres","year":"2004","unstructured":"Peres, M. F. et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24, 735\u2013739 (2004).","journal-title":"Cephalalgia"},{"key":"10883_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0333102415625614","volume":"37","author":"RM van Dongen","year":"2017","unstructured":"van Dongen, R. M. et al. Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia 37, 49\u201363 (2017).","journal-title":"Cephalalgia"},{"key":"10883_CR14","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1\u2013211 (2018).","DOI":"10.1177\/0333102417738202"},{"key":"10883_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1586\/ern.09.93","volume":"9","author":"RB Lipton","year":"2009","unstructured":"Lipton, R. B. & Chu, M. K. Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev. Neurother. 9, 1451\u20131454 (2009).","journal-title":"Expert Rev. Neurother."},{"key":"10883_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/0004-282x20170015","volume":"75","author":"MT Benatto","year":"2017","unstructured":"Benatto, M. T. et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq. Neuropsiquiatr. 75, 153\u2013159 (2017).","journal-title":"Arq. Neuropsiquiatr."},{"key":"10883_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe, F. et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 46, 319\u2013329 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"10883_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0333102416653235","volume":"37","author":"TJ Song","year":"2017","unstructured":"Song, T. J. et al. Anxiety and depression in probable migraine: A population-based study. Cephalalgia 37, 845\u2013854 (2017).","journal-title":"Cephalalgia"},{"key":"10883_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","volume":"32","author":"K Kroenke","year":"2002","unstructured":"Kroenke, K. & Spitzer, R. L. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr. Ann. 32, 509\u2013515 (2002).","journal-title":"Psychiatr. Ann."},{"key":"10883_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","volume":"146","author":"K Kroenke","year":"2007","unstructured":"Kroenke, K., Spitzer, R. L., Williams, J. B., Monahan, P. O. & Lowe, B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann. Intern. Med. 146, 317\u2013325 (2007).","journal-title":"Ann. Intern. Med."},{"key":"10883_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fpsyt.2019.00127","volume":"10","author":"JK Ahn","year":"2019","unstructured":"Ahn, J. K., Kim, Y. & Choi, K. H. The psychometric properties and clinical utility of the korean version of GAD-7 and GAD-2. Front. Psychiatry 10, 127 (2019).","journal-title":"Front. Psychiatry"},{"key":"10883_CR22","first-page":"114","volume":"28","author":"HS Choi","year":"2007","unstructured":"Choi, H. S. et al. Standardization of the Korean version of Patient Health Questionnaire-9 as a screening instrument for major depressive disorder. J. Korean Acad. Fam. Med. 28, 114\u2013119 (2007).","journal-title":"J. Korean Acad. Fam. Med."},{"key":"10883_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"10883_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"10883_CR25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"10883_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1468-2982.2006.01234.x","volume":"27","author":"M Vaccaro","year":"2007","unstructured":"Vaccaro, M. et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia 27, 35\u201340 (2007).","journal-title":"Cephalalgia"},{"key":"10883_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1046\/j.1468-2982.1997.1706652.x","volume":"17","author":"P D'Eufemia","year":"1997","unstructured":"D\u2019Eufemia, P. et al. Erythrocyte and plasma levels of glutamate and aspartate in children affected by migraine. Cephalalgia 17, 652\u2013657 (1997).","journal-title":"Cephalalgia"},{"key":"10883_CR28","first-page":"1079","volume":"2","author":"CF Gasparini","year":"2015","unstructured":"Gasparini, C. F., Ra, S. & Lr, G. Biochemical studies of the neurotransmitter glutamate: A key player in migraine. Austin. J. Clin. Neurol. 2, 1079 (2015).","journal-title":"Austin. J. Clin. Neurol."},{"key":"10883_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1468-2982.1988.0801007.x","volume":"8","author":"R Malmgren","year":"1988","unstructured":"Malmgren, R. & Hasselmark, L. The platelet and the neuron: Two cells in focus in migraine. Cephalalgia 8, 7\u201324 (1988).","journal-title":"Cephalalgia"},{"key":"10883_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1468-2982.2005.01048.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli, P. et al. Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia 26, 409\u2013415 (2006).","journal-title":"Cephalalgia"},{"key":"10883_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11916-007-0216-2","volume":"11","author":"P Sarchielli","year":"2007","unstructured":"Sarchielli, P., Di Filippo, M., Nardi, K. & Calabresi, P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr. Pain Headache Rep. 11, 343\u2013351 (2007).","journal-title":"Curr. Pain Headache Rep."},{"key":"10883_CR32","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/brain\/awx130","volume":"140","author":"R Zielman","year":"2017","unstructured":"Zielman, R. et al. Cortical glutamate in migraine. Brain 140, 1859\u20131871 (2017).","journal-title":"Brain"},{"key":"10883_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-018-0885-8","volume":"19","author":"A Bathel","year":"2018","unstructured":"Bathel, A. et al. Increased thalamic glutamate\/glutamine levels in migraineurs. J. Headache Pain 19, 55 (2018).","journal-title":"J. Headache Pain"},{"key":"10883_CR34","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1523\/JNEUROSCI.0587-16.2016","volume":"36","author":"U Vazana","year":"2016","unstructured":"Vazana, U. et al. Glutamate-mediated blood-brain barrier opening: Implications for neuroprotection and drug delivery. J. Neurosci. 36, 7727\u20137739 (2016).","journal-title":"J. Neurosci."},{"key":"10883_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/biology5040037","volume":"5","author":"RA Hawkins","year":"2016","unstructured":"Hawkins, R. A. & Vi\u00f1a, J. R. How glutamate is managed by the blood-brain barrier. Biology 5, 2 (2016).","journal-title":"Biology"},{"key":"10883_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/0006-3223(88)90052-2","volume":"23","author":"G Alfredsson","year":"1988","unstructured":"Alfredsson, G., Wiesel, F. A. & Tylec, A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. Biol. Psychiatry 23, 689\u2013697 (1988).","journal-title":"Biol. Psychiatry"},{"key":"10883_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1468-2982.1995.1504265.x","volume":"15","author":"G D'Andrea","year":"1995","unstructured":"D\u2019Andrea, G., Cananzi, A. R., Perini, F. & Hasselmark, L. Platelet models and their possible usefulness in the study of migraine pathogenesis. Cephalalgia 15, 265\u2013271 (1995).","journal-title":"Cephalalgia"},{"key":"10883_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1471-4159.1981.tb01701.x","volume":"36","author":"RM Mangano","year":"1981","unstructured":"Mangano, R. M. & Schwarcz, R. The human platelet as a model for the glutamatergic neuron: Platelet uptake of L-glutamate. J. Neurochem. 36, 1067\u20131076 (1981).","journal-title":"J. Neurochem."},{"key":"10883_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0272989X8800800308","volume":"8","author":"JA Hanley","year":"1988","unstructured":"Hanley, J. A. The robustness of the \u201cbinormal\u201d assumptions used in fitting ROC curves. Med. Decis. Making 8, 197\u2013203 (1988).","journal-title":"Med. Decis. Making"},{"key":"10883_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11613\/BM.2007.014","volume":"17","author":"MA Raslich","year":"2007","unstructured":"Raslich, M. A., Markert, R. J. & Stutes, S. A. Selecting and interpreting diagnostic tests. Biochem. Med. 17, 151\u2013161 (2007).","journal-title":"Biochem. Med."},{"key":"10883_CR41","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/14737175.2021.1951236","volume":"21","author":"KS Ferreira","year":"2021","unstructured":"Ferreira, K. S., Dhillon, H. & Velly, A. M. The role of a potential biomarker in patients with migraine: review and new insights. Exp. Rev. Neurother. 21, 817\u2013831 (2021).","journal-title":"Exp. Rev. Neurother."},{"key":"10883_CR42","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3598","volume":"48","author":"P Gormley","year":"2016","unstructured":"Gormley, P. et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat. Genet. 48, 856\u2013866 (2016).","journal-title":"Nat. Genet."},{"key":"10883_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/head.13053","volume":"57","author":"HG Sutherland","year":"2017","unstructured":"Sutherland, H. G. & Griffiths, L. R. Genetics of migraine: Insights into the molecular basis of migraine disorders. Headache 57, 537\u2013569 (2017).","journal-title":"Headache"},{"key":"10883_CR44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrn3057","volume":"12","author":"S Akerman","year":"2011","unstructured":"Akerman, S., Holland, P. R. & Goadsby, P. J. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 12, 570\u2013584 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"10883_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0304-3959(95)00095-X","volume":"64","author":"DA Bereiter","year":"1996","unstructured":"Bereiter, D. A., Bereiter, D. F. & Hathaway, C. B. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat. Pain 64, 179\u2013189 (1996).","journal-title":"Pain"},{"key":"10883_CR46","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1523\/JNEUROSCI.04-08-02133.1984","volume":"4","author":"JT Greenamyre","year":"1984","unstructured":"Greenamyre, J. T., Young, A. B. & Penney, J. B. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J. Neurosci. 4, 2133\u20132144 (1984).","journal-title":"J. Neurosci."},{"key":"10883_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","volume":"15","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann, J. & Charles, A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics 15, 361\u2013370 (2018).","journal-title":"Neurotherapeutics"},{"key":"10883_CR48","doi-asserted-by":"publisher","first-page":"C1399","DOI":"10.1152\/ajpcell.00386.2005","volume":"290","author":"H Parfenova","year":"2006","unstructured":"Parfenova, H. et al. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: Contributions of HO-1 and HO-2 to cytoprotection. Am. J. Physiol. Cell Physiol. 290, C1399-1410 (2006).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10883_CR49","first-page":"97","volume":"61","author":"A Mandal","year":"2013","unstructured":"Mandal, A., Mishra, S. & Mandal, P. Sex specific differences in GABA and glutamate levels in response to cigarette smoke. Physiol. Res. 61, 97\u2013111 (2013).","journal-title":"Physiol. Res."},{"key":"10883_CR50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ajhb.22787","volume":"28","author":"H Nakamura","year":"2016","unstructured":"Nakamura, H. et al. Plasma amino acid profiles in healthy East Asian subpopulations living in Japan. Am. J. Hum. Biol. 28, 236\u2013239 (2016).","journal-title":"Am. J. Hum. Biol."},{"key":"10883_CR51","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1515\/JPEM.2011.270","volume":"24","author":"P Yi","year":"2011","unstructured":"Yi, P. et al. Establishment of reference range of plasma amino acids for younger Chinese children by reverse phase HPLC. J. Pediatr. Endocrinol. Metab. 24, 733\u2013738 (2011).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10883_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fpsyt.2018.00713","volume":"9","author":"C Madeira","year":"2018","unstructured":"Madeira, C. et al. Blood levels of glutamate and glutamine in recent onset and chronic schizophrenia. Front. Psychiatry 9, 713 (2018).","journal-title":"Front. Psychiatry"},{"key":"10883_CR53","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1526-4610.2008.01133.x","volume":"48","author":"N Schmitz","year":"2008","unstructured":"Schmitz, N. et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache 48, 1044\u20131055 (2008).","journal-title":"Headache"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10883-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:04:13Z","timestamp":1669341853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10883-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10883"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10883-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Min Kyung Chu was a site investigator for a multicenter trial sponsored by Otsuka Korea, Novartis, International AG, and Eli Lilly and Co. He also worked as an advisory member for Teva, and has received lecture honoraria from Allergan Korea, Handok-Teva, and Yuyu Pharmaceutical Company within the past 24\u00a0months. Furthermore, he received grants from the Yonsei University College of Medicine (2018\u201332-0037) and the National Research Foundation of Korea (2019R1F1A1053841). Chae Gyu Park declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6921"}}